Article
Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
Molecular cancer therapeutics - 1 Apr 2013
Bhaskaran Shylesh, Dileep Kalarikkal V, Deepa Sathyaseelan S, Sadasivan Chittalakkottu, Klausner Mitch, Krishnegowda Naveen K, Tekmal Rajeshwar R, VandeBerg John L, Nair Hareesh B
Abstract excerpt
Mutation in the BRAF gene (BRAFV600E) exists in nearly 70% of human melanomas. Targeted therapy against BRAFV600E kinase using a recently identified RAF-selective inhibitor, PLX4032, has been successful in early clinical trials. However, in patients with the normal BRAF allele (wild-type), PLX4032 is protumorigenic. This conundrum identifies the unmet need for novel therapeutic agents to target BRAFV600E kinase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.